Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickening

1. Kannel WB , McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035–8.

2. Castelli WP , Wilson PW , Levy D , Anderson K. Cardiovascular risk factors in the elderly. Am J Cardiol 1989;63:12H–19H.

3. Temelkova-Kurktschiev T , Köhler C , Schaper F et al. Beziehung zwischen verschiedenen Stadien der Glukosetoleranz, etablierten Risikofaktoren für Arteriosklerose und Intima-Media. Dicke (IMD) der A. carotis communis. Diabetes und Stoffwechsel 1998;7:227–32.

4. Yamanouchi T , Minoda S , Yabuuchi M et al. Plasma 1, 5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 1989;38:723–9.

5. Yamanouchi T , Moromizato H , Shinohara T et al. Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1, 5–anhydroglucitol. Metabolism 1992;41:862–7.

6. Fukumura Y , Tajima S , Oshitani S et al. Fully enzymatic method for determining 1, 5-anhydro-D-glucitol in serum. Clin Chem 1994;40:2013–16.

7. Fontbonne A , Charles MA , Thibult N et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study 15-year follow-up. Diabetologia 1991;34:356–61.

8. Fuller JH , Shipley MJ , Rose G , Jarrett RJ , Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ (Clin Res Ed) 1983;287:867–70.

9. Hanefeld M , Koehler C , Schaper F , Fuecker K , Henkel E , Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999;144:229–35.

10. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2:131–41.

11. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS). Lancet 1998;352:837–53.